作为辅助剂的ORF病毒增强了对PCV2亚单元疫苗的免疫反应
Jie Sun1, Jun Ma1, Longfei Chen1
1National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; The Key Laboratory of Preventive Veterinary Medicine in Hubei Province, Cooperative Innovation Center for Sustainable Pig Production, Wuhan 430070, China.
Veterinary microbiology
|April 19, 2024
概括
奥尔夫病毒 (ORFV) 作为一种强有力的辅助剂,增强了对猪肉循环病毒2型 (PCV2) 亚单元疫苗的免疫反应. 这种新型辅助剂可以增强幽默和细胞免疫力,减少小鼠的病毒载量和病理.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 奥尔夫病毒 (ORFV),一个帕拉波克斯病毒,表现出强大的免疫激活特性.
- ORFV显示出作为免疫调节剂的潜力.
- 开发有效的辅助剂对于提高疫苗疗效至关重要.
研究的目的:
- 评估Orf病毒 (ORFV) 作为一种新型辅助剂,用于猪病毒2型 (PCV2) 亚单元疫苗.
- 评估ORFV对PCV2体 (Cap) 蛋白免疫小鼠免疫反应的影响.
- 确定ORFV作为辅助剂在改善疫苗诱导免疫力的潜力.
主要方法:
- 小鼠用PCV2 Cap蛋白与非活化或活衰减ORFV或辅助剂结合免疫.
- 分析了免疫反应,包括细胞因子的产生 (IL-1β,IL-6,TNF-α) 和Th1/Th2细胞因子的分泌.
- 用PCV2挑战小鼠,以评估疫苗的有效性,测量病毒载量和肺病理.
主要成果:
- 不活化和活衰减ORFV激活的树突细胞和上调的关键细胞因子 (IL-1β,IL-6,TNF-α).
- 与辅助剂相比,ORFV辅助剂显著增强了幽默和细胞免疫力.
- ORFV辅助剂促进了混合的Th1/Th2免疫反应,并降低了PCV2病毒载量和肺病理.
结论:
- 奥尔夫病毒 (ORFV) 作为一种有效的新型辅助剂,增强PCV2亚单元疫苗的免疫性.
- ORFV改善了自适应性免疫反应,为疫苗开发提供了一个有前途的战略.
- 该研究表明ORFV的潜在应用在兽医和潜在的人类疫苗中作为多功能辅助剂.
相关概念视频
01:51Vaccinations
44.4K
Overview
44.4K
01:29Immune Response Against Viral Pathogens
777
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
777
01:22Development of Immunocompetence
305
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
305